EMG
FPRX

Ellington Management Group’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Ellington Management Group’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-8,500
Closed -$345K – 551
2016
Q1 		$345K Buy
+8,500
New +$292K 0.15% 200
2015
Q2 		– Sell
-8,900
Closed -$203K – 958
2015
Q1 		$203K Buy
+8,900
New +$225K 0.04% 595

Other funds holding FPRX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return

Ellington Management Group's FPRX Position: Q2 2016 in Review

Ellington Management Group sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2016, closing a stake of 8,500 shares — an estimated $345K sold.

Ellington Management Group first reported a position in FPRX in Q1 2015 and held it in 2 quarters. The position peaked at $345K in Q1 2016. 170 funds tracked by Wall St. Rank hold FPRX as of Q2 2016.

  • Ellington Management Group reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2016 after selling out during the quarter.
  • Ellington Management Group sold 8,500 Five Prime Therapeutics, Inc. shares in Q2 2016, an estimated $345K.
  • Ellington Management Group first reported a position in Five Prime Therapeutics, Inc. in Q1 2015 and held it in 2 quarters.
  • Ellington Management Group's Five Prime Therapeutics, Inc. position peaked at $345K in Q1 2016.
  • 170 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2016.

Based on Ellington Management Group's 13F filing for Q2 2016, filed 15 Aug 2016.